指南与共识膀胱癌与上尿路尿路上皮癌

EAU非肌层浸润性膀胱癌预后风险分组更新:纳入WHO 2004/2016与1973分级

European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
指南 / 共识 · Eur Urol · 2021-01-06

基于3401例原发性NMIBC患者个体数据,采用多变量Cox模型更新EAU预后风险分组,纳入WHO 1973与2004/2016两种分级系统,将患者分为低、中、高及新增极高危四组,5年进展概率从<1%至>40%不等。

要点

  • 更新后的EAU风险分组同时纳入WHO 1973和2004/2016分级系统。
  • 新增极高危组,5年进展概率最高超过40%,需及时调整治疗策略。
  • 风险因素包括肿瘤分期、分级、伴发原位癌、肿瘤数目、大小和年龄。

核心结论

  • 研究提供了更新的EAU预后风险分组,可用于指导患者治疗和随访。
  • 纳入WHO 2004/2016和1973分级后,识别出新的极高危组,泌尿外科医生应及时评估并调整治疗策略。

研究设计与样本

  • 多中心回顾性收集原发性NMIBC患者个体数据,来自EAU NMIBC指南委员会成员所在机构。
  • 共纳入3401例接受TURBT±膀胱内化疗的患者。
  • 拟合多变量Cox比例风险模型,主要终点为进展至肌层浸润性疾病或远处转移的时间。

主要发现

  • 多变量分析中,肿瘤分期、WHO 1973/2004-2016分级、伴发原位癌、肿瘤数目、肿瘤大小和年龄用于构建四个风险组。
  • 四个风险组的5年进展概率从<1%至>40%不等。

关键数值与推荐

  • 风险分组基于肿瘤分期、WHO 1973/2004-2016分级、伴发原位癌、肿瘤数目、肿瘤大小和年龄。
  • 患者分为低危、中危、高危和新增的极高危组。
  • 5年进展概率范围从<1%至>40%。

临床怎么用

  • 使用更新后的EAU风险分组为NMIBC患者提供治疗和随访建议。
  • 对极高危组患者应及时评估并必要时调整治疗策略。

局限性

  • 数据为回顾性收集。
  • 缺乏中心病理复核。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do not, however, take into account the widely used World Health Organization (WHO) 2004/2016 grading classification and are based on patients treated in the 1980s. OBJECTIVE: To update EAU prognostic factor risk groups using the WHO 1973 and 2004/2016 grading classifications and identify patients with the lowest and highest probabilities of progression. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for primary NMIBC patients were collected from the institutions of the members of the EAU NMIBC guidelines panel. INTERVENTION: Patients underwent TURBT followed by intravesical instillations at the physician's discretion. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox proportional-hazards regression models were fitted to the primary endpoint, the time to progression to muscle-invasive disease or distant metastases. Patients were divided into four risk groups: low-, intermediate-, high-, and a new, very high-risk group. The probabilities of progression were estimated using Kaplan-Meier curves. RESULTS AND LIMITATIONS: A total of 3401 patients treated with TURBT ± intravesical chemotherapy were included. From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%. Limitations include the retrospective collection of data and the lack of central pathology review. CONCLUSIONS: This study provides updated EAU prognostic factor risk groups that can be used to inform patient treatment and follow-up. Incorporating the WHO 2004/2016 and 1973 grading classifications, a new, very high-risk group has been identified for which urologists should be prompt to assess and adapt their therapeutic strategy when necessary. PATIENT SUMMARY: The newly updated European Association of Urology prognostic factor risk groups for non-muscle-invasive bladder cancer provide an improved basis for recommending a patient's treatment and follow-up schedule.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sylvester RJ, Rodríguez O, Hernández V, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021. PMID: 33419683. doi:10.1016/j.eururo.2020.12.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。